GlobeNewswire

YPO Welcomes 2018 YPO Innovation Week Sponsors

Dela

DALLAS, April 24, 2018 (GLOBE NEWSWIRE) -- YPO, the world's premier leadership organization of chief executives, announced today that Techstars has joined as a gold sponsor and Geniecast, Emplify and Telluride are silver sponsors of the 2018 YPO Innovation Week

YPO Innovation Week sponsors offer valuable insight, key connections and respected expertise that made the world's largest and most impactful innovation initiative possible.

"YPO Innovation Week brings together some of the most innovative and disruptive leaders around the world," said YPO CEO Scott Mordell. "We are so pleased to partner with these prestigious and forward-thinking organizations and businesses to help elevate the week's experiences for our members and take innovation to the next level."

During the week of 7-11 May 2018, YPO will host innovation events across the globe from Sydney, Australia to London, England; Tel Aviv, Israel to New York, New York, USA; Santo Domingo, Dominican Republic to Palo Alto, California, USA and Nairobi, Kenya, and more.

The mission of YPO Innovation Week is to drive innovation and transformation across a diverse range of industries and sectors through signature events, live interactive video casts and livestream events across more than 30 countries. Business leaders and pioneering thinkers will engage in a weeklong forum discussing the most important innovations affecting business today, including augmented and virtual reality, vehicle technology, digital imaging, wearables, smart home, sensors and more.

"We welcome these prestigious partners and their participation in the 2018 YPO Innovation Week," said YPO Innovation Week Chair Keith Alper. "With their support, we will truly be able to overturn conventional thinking and inspire business leaders to accelerate what's next."

Gold Sponsors
Techstars is featuring Techstars Founders who will deliver pitches at several YPO Innovation Week events, including the Global FinTech Summit, the World Technology Summit and the NYSE Closing Bell event.

Silver Sponsors
Geniecast is hosting digital events throughout YPO Innovation Week via two-way video broadcast.

Emplify's CEO Santiago Jaramillo, a YPO member, will present on the future of work at the Silicon Valley Summit and World Technology Summit.

Telluride is hosting a virtual reality space at the Silicon Valley Summit and providing an exclusive prize package for YPO Global Innovation Award finalists.

About YPO 

The premier leadership organization of chief executives in the world.

YPO is the global platform for chief executives to engage, learn and grow. YPO members harness the knowledge, influence and trust of the world's most influential and innovative business leaders to inspire business, personal, family and community impact.

Today, YPO empowers more than 25,000 members in more than 130 countries, diversified among industries and types of businesses. Altogether, YPO member-run companies employ more than 16 million people and generate USD6 trillion in annual revenues.

Leadership. Learning. Lifelong. For more information, visit YPO.org.

About Techstars
Techstars is the worldwide network that helps entrepreneurs succeed. Techstars founders connect with other entrepreneurs, experts, mentors, alumni, investors, community leaders, and corporations to grow their companies. Techstars operates four divisions: Techstars Startup Programs, Techstars Mentorship-Driven Accelerator Programs, Techstars Corporate Innovation Partnerships, and the Techstars Venture Capital Fund. Techstars portfolio includes more than 1,300 companies with a market cap of $12 billion. www.techstars.com

About Geniecast
Geniecast is transforming the way the world connects people, ideas, and inspiration. We are curators, producers, and distributors of the world's largest online marketplace of thought leaders, athletes, speakers, celebrities, facilitators and more - all available via two-way, live video broadcast. Join us in the quest to inspire, lead, and evolve. At Geniecast, we strive to offer human-centric client services through great people and clever technology, one transaction at a time. From a warm welcome to individualized attention, we engage with you, one connection at a time. And, when you least expect it, we plan to surprise you with an extra touch, one experience at a time. To learn more, visit https://geniecast.com/.

About Emplify
Emplify, the industry leader in data-driven employee analytics and action-enabling insights for business leaders, helps executives leverage employee insights to make their workforce more successful. Backed by decades of research in human psychology and neuroscience, Emplify InsightsTM blends employee engagement best practices and hands-on expert coaching into an agile feedback system that's simple yet more effective than historic annual employee surveys, and more trustworthy than modern pulse surveys. Emplify is trusted by companies like Ivy Tech Community College, Herff Jones, Harley Davidson, Cheetah Digital, Crew Carwash, Yamaha, and many others. Learn more at emplify.com.

About Telluride
Forty-five minutes from the nearest stoplight, at the end of a incredibly beautiful box canyon sits Telluride, Colorado, a National Historic Landmark surrounded by the highest concentration of 13,000' and 14,000' peaks in the United States. Above Telluride is a modern mountain village connected by a gondola, the only one of its kind in North America. While the ski terrain is world-renowned, the resort is truly defined by a collection of intimate and unmatched experiences. With your first walk down the historic main street, you'll find the character and charm of Telluride as special as the majestic San Juan Mountains. To learn more, visit www.tellurideskiresort.com .

Contact:
YPO
Linda Fisk
Office: +1 972 629 7305 (United States)
Mobile: +1 972 207 4298 
press@ypo.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: YPO via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum